Liposomes, spherical lipid bilayers enclosing an aqueous space, have become an important class of drug carriers. This review describes the usefulness of scintigraphic imaging during the development of liposome-based drugs. This imaging modality is particularly helpful for tracking the distribution of liposomes in the body, monitoring the therapeutic responses following administration of liposome-based drugs, and investigating the physiological responses associated with liposome administration. Scintigraphy also can be used to monitor the therapeutic responses of patients given approved liposomal drugs. Several examples describing the potential of this imaging modality during both the preclinical formulation and clinical trial stages of liposomal drug development are included. Techniques for radiolabeling liposomes as well as methods for producing scintigraphic images are also described.
Mastrobattista E, Koning GA, Storm G.Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Delivery Rev. 1999; 40:103-127.
4.
Torchilin VP. Liposomes as delivery agents for medical imaging. Mol Med Today. 1996; 2:242-249.
5.
Campos S, Shapiro CL. Clinical evaluation of liposomal anthracyclines. In: Janoff AS, ed. Liposomes Rational Design. New York: Marcel Dekker;1999:363-377.
6.
Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther. 1999; 24:249-257.
7.
Florence AT. Introduction: liposomes as pharmaceuticals. In: Janoff AS, ed. Liposomes Rational Design. New York: Marcel Dekker; 1999:xix-xxxi.
8.
Corvo ML, Boerman OC, Oyen WJ, et al. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm Res. 2000; 17:600-606.
9.
Delanian S, Baillet F, Huart J, et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol. 1994; 32:12-20.
10.
Gregoriadis G, McCormack B, Obrenovic M, et al. Vaccine entrapment in liposomes. Methods. 1999; 19:156-162.
11.
Kim A, Yun MO, Oh YK, et al. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm. 1999; 180:75-81.
12.
Ludewig B, Barchiesi F, Pericin M, et al. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective anti-viral and anti-tumour immunity. Vaccine. 2000; 19:23-32.
13.
Mahato RI, Takakura Y, Hashida M.Development of targeted delivery systems for nucleic acid drugs. J Drug Target. 1997; 4:337-357.
14.
Templeton NS, Lasic DD. New directions in liposomal gene delivery. Mol Biotechnol. 1999; 11:175-180.
15.
Wong JP, Yang H, Nagata L, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine. 1999; 17:1788-1795.
16.
Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Delivery Rev. 1999; 37:13-32.
17.
Tilcock C.Delivery of contrast agents for magnetic resonance imaging, computed tomography, nuclear medicine and ultrasound. Adv Drug Delivery Rev.1999; 37:33-51.
18.
Kostarelos K, Emfietzoglou D.Liposomes as carriers of radionuclides: from imaging to therapy. J Liposome Res. 1999; 9:429-460.
19.
Phillips W, Goins B.Targeted delivery of imaging agents by liposomes. In: Torchilin VP, ed. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL: CRC Press;1995:149-173.
20.
Proffitt R, Williams L, Presant C, et al. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med. 1983; 24:45-51.
21.
Phillips WT, Rudolph AS, Goins B, et al. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nucl Med Biol.1992; 19:539-547.
22.
Gabizon A, Huberty J, Straubinger RM, et al. An improved method for in vivo tracing and imaging of liposomes using a gallium-67-desferoxamine complex. J Liposome Res. 1988; 1:123-135.
23.
Oku N.Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Delivery Rev. 1999; 37:53-61.
24.
Patel HM, Boodle KM, Vaughan-Jones R.Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-Technetium to represent intact liposomes in lymph nodes. Biochim Biophys Acta.1984; 801:76-86.
25.
Barratt GM, Tuzel NS, Ryman BE. The labeling of liposomal membranes with radioactive technetium. In: Gregoriadis G, ed. Liposome Technology. Boca Raton, FL: CRC Press; 1984:94-105.
26.
Laverman P, Dams E, Oyen W, et al. A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative. J Nucl Med. 1999; 40:192-197.
27.
Barenholz Y, Amselem S, Goren D, et al. Stability of liposomal doxorubicin formulation: problems and prospects. Med Res Rev. 1993; 13:449-491.
28.
Ogihara-Umeda I, Sasaki T, Nishigori H.Development of a liposome-encapsulated radionuclide with preferential tumor accumulation—the choice of radionuclide and chelating ligand. Nucl Med Biol.1992; 19:753-757.
29.
Graham LS, Muehllehner G.Anger Scintillation Camera. In: Sandler MP, ed. Diagnostic Nuclear Medicine. Baltimore: Williams & Wilkins; 1996:81-92.
Phelps ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41:661-681.
32.
Goins BA, Phillips WT. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog Lipid Res. 2001; 40:95-123.
33.
Farmer MC, Gaber BP. Liposome encapsulated hemoglobin as an artificial oxygen-carrying system. Methods Enzymol. 1987; 149:184-200.
34.
Rudolph AS, Klipper RW, Goins B, et al. In vivobiodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc Natl Acad Sci USA.1991; 88:10976-10980.
35.
Phillips W, Klipper R, Awasthi V, et al. Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther. 1999; 288:665-670.
36.
Presant CA, Blayney D, Proffitt RT, et al. Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet. 1990; 335:1307-1309.
37.
Tulpule A, Yung R, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s sarcoma. J Clin Oncol.1998; 16:3369-3374.
38.
Anonymous. Liposomal daunorubicin marketed for HIV-related Kaposi’s sarcoma. Am J Health Syst Pharm. 1996; 53:1550-1605.
39.
Cheung TW, Remick SC, Azarnia N, et al. AIDS-related Kaposi’s sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res. 1999; 5:3432-3437.
40.
Anonymous. Doxorubicin liposome formulation gains marketing approval. Am J Health Syst Pharm.1996; 53:116-119.
41.
Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m labeled liposomes in feline sarcomas. Clin Cancer Res. 2000; 6:3748-3755.
42.
Dams ET, Corstens FH. Lessons for medicine and nuclear medicine research. Eur J Nucl Med. 1999; 26:311-313.
43.
Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000; 18:1689-1695.
44.
Strauss LG. Positron emission tomography: current role for diagnosis and therapy monitoring in oncology. Oncologist. 1997; 2:381-388.
